05/23/2022 | Press release | Distributed by Public on 05/23/2022 06:09
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago. Among the 19 abstracts are oral presentations highlighting the use of real-world data to identify resistance to early treatment in advanced breast cancer and the use of enhanced biomarker analysis to evaluate progression-free survival data in metastatic breast cancer therapy.
"We look forward to sharing an array of robust data at ASCO that demonstrate the utility of our blood tests to help healthcare professionals optimize care for patients at all stages of the disease-from detecting early-stage cancers to identifying the presence of residual disease and delivering insights that inform treatment to improve outcomes," said Helmy Eltoukhy, Guardant Health co-CEO. "We'll be presenting data from retrospective and real-world analyses that show how blood-based tests provide critical insights at every step of a patient's treatment journey, and analytics that contribute to the broader scientific community's understanding of some of the most challenging cancers."
Full List of Guardant Health Presentations
Guardant360
Guardant Reveal
Guardant360 Response
GuardantINFORM
GuardantOMNI
Shield LDT - CRC Screening
Next generation Shield - Multi-Cancer Screening
The full abstracts will be available on the official ASCO website on May 26, 2022.
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2021 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005234/en/
Investor Contact:
Alex Kleban
[email protected]
+1 657-254-5417
Media Contact:
Michele Rest
[email protected]
+1 215-910-2138
Source: Guardant Health, Inc.
Multimedia Files: